PharmOncology

Thoughts on all the NCCN preferred second-line DLBCL regimens, other than CAR-T and transplant

The challenges of targeting BRCA mutations in all cancersTumor lineage shapes BRCA-mediated phenotypes: https://pmc.ncbi.nlm.nih.gov/articles/PMC7048239/

Thoughts on using pCR as a surrogate endpointDESTINY-Breast11: https://pubmed.ncbi.nlm.nih.gov/41130363/Clinical Cancer Research publication on pCR, EFS and OS: https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-NeoadjuvantBMJ publication on pCR, EFS and OS: https://www.bmj.com/content/375/bmj-2021-066381FDA-sponsored analysis: https://pubmed.ncbi.nlm.nih.gov/24529560/KATHERINE trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1814017

Episode explaining the Fc receptor on antibodies, with some examples!Lessons from TIGIT antibodies: https://pubmed.ncbi.nlm.nih.gov/41389708/

Discussion on the CIRCULATE trialASCO CIRCULATE abstract: https://www.asco.org/abstracts-presentations/260542Real-world experience of circulating tumor DNA testing in resectable colorectal cancer: a Japanese single-institution observational study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12847216/ASCO GI abstract: Pathologic determinants of ctDNA-shedding in colorectal cancer metastases. https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.183Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables https://www.sciencedirect.com/science/article/pii/S0169500202001721

Why it's hard to compare adverse events across trialsCapitello-291: https://www.nejm.org/doi/full/10.1056/NEJMoa2214131Capitello-281: https://pubmed.ncbi.nlm.nih.gov/41120017/

RASolute 302:https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

What we do and do not understand about antibody drug conjugate sequencing.Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(26)00007-9/fulltextPost mortem sacituzumab govitecan study:https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/

Why HRR gene mutations are not the perfect biomarker. PROpel trial: thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-0/fulltextTALAPRO-2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstractTRITON-3 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

Some thoughts on how to interpret ctDNA trials that look to validate it as a predictive biomarker

There is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.